GSK Q2 Adj. EPS $0.97 Beats $0.87 Estimate, Sales $8.97B Beat $8.97B Estimate
Portfolio Pulse from Benzinga Newsdesk
GSK (NYSE:GSK) reported Q2 earnings of $0.97 per share, beating the analyst consensus estimate of $0.87 by 11.49%. The company also reported quarterly sales of $8.99 billion, beating the estimate of $8.97 billion by 0.22%. This represents a 3.14% increase over sales from the same period last year.
July 26, 2023 | 7:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Q2 earnings and sales beat estimates, which could lead to a positive short-term impact on the stock.
GSK's earnings and sales for Q2 have exceeded analyst estimates, which is typically a positive signal for investors and can lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100